New Enzyme Discovery in HPV Research

Targeting HPV for Cancer Treatment

Scientists have identified an enzyme utilized by the human papillomavirus (HPV) that may serve as a target for combating cervical, mouth, and anal cancers. Despite the availability of a vaccine for HPV prevention, it remains inaccessible in many regions, and some individuals decline vaccination due to religious beliefs and cost concerns. Consequently, HPV persists as the most prevalent sexually transmitted infection, affecting over 79 million people in the United States.

Prevalence of HPV-Related Cancers

Nearly all cervical cancers in women are attributable to HPV infections, with approximately 500,000 new cases reported globally, resulting in a death rate of about 54%. The virus also contributes to over 130,000 cases of mouth cancer and accounts for one in every 100,000 anal cancer cases. While HPV often resolves without causing health issues, it can also lead to genital warts and various cancers. Screening methods, such as pap smears, are available for cervical cancer, but specific tests for HPV status are lacking. Many individuals learn of their HPV status only upon experiencing health complications, highlighting the need for innovative treatment alternatives.

Breakthrough Findings from the University of Virginia

Understanding the Role of USP46

Researchers at the University of Virginia School of Medicine have made a significant discovery regarding HPV, revealing that the virus employs an enzyme known as USP46 to facilitate tumor formation and growth. This enzyme presents a viable target for pharmacological intervention, as it possesses a pocket that allows chemicals to inhibit and deactivate its function.

The study, published in the journal Molecular Cell, outlines the methodology used to identify the enzyme. Researchers conducted multiple assays and experiments involving cells and mice to investigate the enzyme’s functionality and its potential implications for human health. Mice were injected with tumors to evaluate the effects of blocking USP46 on tumor growth.

Potential for New Treatment Options

Given that enzymes can be effectively targeted by pharmaceutical compounds, HPV cells that depend on USP46 may be candidates for treatments designed to inactivate this enzyme. The research team is currently screening various chemicals to identify those that can hinder USP46 activity, potentially leading to the development of new drugs capable of halting the progression of HPV-related cancers. Although the initial studies focused on early-stage cervical cancer cells, the findings may have broader implications for individuals affected by HPV.

While the assays used in this research are not easily applicable in clinical settings, particularly in developing nations with limited healthcare resources, the identification of compounds that can effectively inhibit USP46 could pave the way for affordable treatment options for HPV-infected patients worldwide.

Conclusion

The ongoing investigation into the role of USP46 in HPV-related cancers holds promise for future therapeutic strategies. As researchers continue to explore potential drug developments, there is hope for improving outcomes for those affected by HPV.

References

Centers for Disease Control and Prevention (CDC). Genital HPV Infection – Fact Sheet. Division of STD Prevention, National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention. Page last updated November 16, 2017.
Kiran, S. et al. The Deubiquitinase USP46 Is Essential for Proliferation and Tumor Growth of HPV-Transformed Cancers. Molecular Cell. Volume 72, Issue 5, P823-835.E5, December 06, 2018.